Chemomab (formerly Anchiano Therapeutics Ltd.) is a clinical-stage biotech company that specializes in the development of antibodies for the treatment of immune-mediated and fibrotic (scarring of tissue) disorders including orphan indications. The leading compound generated positive Phase Ib trial results for Primary Sclerosing Cholangitis (“PSC”) – a chronic progressive cholestatic disease of the liver characterized by inflammation and strictures of the biliary tree inside and/or outside the liver – and is currently conducting a Phase IIa trial. In addition, Chemomab is advancing in parallel two additional Phase II trials for Non-Alcoholic Steatohepatitis (“NASH”), the liver manifestation of a metabolic disorder and the severe form of non-alcoholic fatty liver disease, and for scleroderma, a rare chronic autoimmune disease that is characterized by chronic inflammation, fibrosis of the skin and internal organs as well as vascular damage.